CA3030930A1 - Analogues de l'insuline - Google Patents

Analogues de l'insuline Download PDF

Info

Publication number
CA3030930A1
CA3030930A1 CA3030930A CA3030930A CA3030930A1 CA 3030930 A1 CA3030930 A1 CA 3030930A1 CA 3030930 A CA3030930 A CA 3030930A CA 3030930 A CA3030930 A CA 3030930A CA 3030930 A1 CA3030930 A1 CA 3030930A1
Authority
CA
Canada
Prior art keywords
absent
leu
val
glu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3030930A
Other languages
English (en)
Inventor
John Gerbrandt Tasman Menting
Brian Smith
Danny Hung-Chieh Chou
Helena SAFAVI-HEMAMI
Michael Colin Lawrence
Olivera M. BALDOMERO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
University of Utah Research Foundation Inc
Original Assignee
Walter and Eliza Hall Institute of Medical Research
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016902883A external-priority patent/AU2016902883A0/en
Application filed by Walter and Eliza Hall Institute of Medical Research, University of Utah Research Foundation Inc filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of CA3030930A1 publication Critical patent/CA3030930A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des analogues de l'insuline, en particulier des analogues de l'insuline présentant des chaînes B raccourcies. La présente invention concerne également la structure cristalline de l'insuline provenant du venin d'escargots marins, ainsi que des procédés d'utilisation du cristal et des informations structurales associées pour cribler et concevoir des analogues d'insuline qui interagissent avec ou modulent le récepteur de l'insuline. La présente invention concerne également des procédés thérapeutiques et prophylactiques utilisant les analogues de l'insuline.
CA3030930A 2016-07-22 2017-07-21 Analogues de l'insuline Pending CA3030930A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016902883 2016-07-22
AU2016902883A AU2016902883A0 (en) 2016-07-22 Insulin Analogs
US201762483118P 2017-04-07 2017-04-07
US62/483,118 2017-04-07
PCT/AU2017/050758 WO2018014091A1 (fr) 2016-07-22 2017-07-21 Analogues de l'insuline

Publications (1)

Publication Number Publication Date
CA3030930A1 true CA3030930A1 (fr) 2018-01-25

Family

ID=60991677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030930A Pending CA3030930A1 (fr) 2016-07-22 2017-07-21 Analogues de l'insuline

Country Status (3)

Country Link
AU (1) AU2017298565B2 (fr)
CA (1) CA3030930A1 (fr)
WO (1) WO2018014091A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155804B2 (en) 2016-07-11 2021-10-26 Board Of Regents, The University Of Texas System Recombinant polypeptides comprising selenocysteine and method for producing the same
CR20190096A (es) 2016-07-22 2019-09-16 Walter & Eliza Hall Inst Medical Res Análogos de insulina
CN109803679A (zh) 2016-08-30 2019-05-24 得克萨斯州大学系统董事会 在基因组重新编码生物体中生产硒代生物制剂
WO2018187568A1 (fr) * 2017-04-07 2018-10-11 University Of Utah Research Foundation Analogues d'insuline et procédés d'utilisation
KR20210029210A (ko) * 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
CN114675019B (zh) * 2022-02-10 2022-12-16 江苏省人民医院（南京医科大学第一附属医院） 一种检测胰岛素受体胞外段抗体的试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095443A1 (fr) * 2004-03-31 2005-10-13 Cardio Incorporated Système d'administration médicamenteuse utilisant un peptide modifié
US7790677B2 (en) * 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP5890516B2 (ja) * 2011-06-17 2016-03-22 ハロザイム インコーポレイテッド ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法

Also Published As

Publication number Publication date
AU2017298565A1 (en) 2019-02-21
AU2017298565B2 (en) 2021-08-19
WO2018014091A1 (fr) 2018-01-25

Similar Documents

Publication Publication Date Title
US12410228B2 (en) Insulin analogs
AU2017298565B2 (en) Insulin analogs
Armishaw et al. α-Selenoconotoxins, a new class of potent α7 neuronal nicotinic receptor antagonists
US7225083B2 (en) Crystallographic structure of the androgen receptor ligand binding domain
US8377701B2 (en) Specific ligands to sortilin
EP2411038B1 (fr) Peptides de l'hormone parathyroïdienne et peptides de la protéine apparentée à l'hormone parathyroïdienne ainsi que des procédés d'utilisation
EP2901154B1 (fr) Structure d'insuline dans un complexe avec des régions terminales en n et en c de la chaîne alpha du récepteur de l'insuline
Kosinová et al. Insight into the structural and biological relevance of the T/R transition of the N-terminus of the B-chain in human insulin
US20100248974A1 (en) Crystal structure of cd147 extracellular region and use thereof
EP1385885B1 (fr) Fragments du recepteur orphelin apparente aux recepteurs de l'acide retinoique (ror) comportant le domaine de liason aux ligands (lbd), la structure cristalline du lbd du ror-beta, et leurs applications
EP1265927B1 (fr) Cristal
NZ750355B2 (en) Insulin analogs
Erskine et al. Structure of the neuronal protein calexcitin suggests a mode of interaction in signalling pathways of learning and memory
Watson Insulin analogues for insulin receptor studies and medical applications

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220505

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240905

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250211

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250618

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250618

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250711

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250711

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251015